Targeting the Endothelin A Receptor in IgA Nephropathy.
Kidney Int Rep
; 8(11): 2198-2210, 2023 Nov.
Article
in En
| MEDLINE
| ID: mdl-38025243
ABSTRACT
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and carries a substantial risk of kidney failure. New agency-approved therapies, either specifically for IgAN or for chronic kidney disease (CKD) in general, hold out hope for mitigating renal deterioration in patients with IgAN. The latest addition to this therapeutic armamentarium targets the endothelin-A receptor (ETAR). Activation of ETAR on multiple renal cell types elicits a host of pathophysiological effects, including vasoconstriction, cell proliferation, inflammation, apoptosis, and fibrosis. Blockade of ETAR is renoprotective in experimental models of IgAN and reduces proteinuria in patients with IgAN. This review discusses the evidence supporting the use of ETAR blockade in IgAN as well as addressing the potential role for this class of agents among the current and emerging therapies for treating this disorder.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Kidney Int Rep
Year:
2023
Type:
Article
Affiliation country:
United States